Drug Delivery Platforms
•230 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (230)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
Drug delivery platforms are highlighted as differentiators enabling scaled manufacturing.
|
$982.80B |
$1038.79
+0.56%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
Drug delivery platform concepts (e.g., formulation/formulation technologies) are implied by delivery enhancements.
|
$77.69B |
$732.71
-1.24%
|
|
BDX
Becton, Dickinson and Company
BD develops drug delivery platforms and related biologic‑delivery solutions for therapeutics including GLP‑1s and wearables.
|
$59.36B |
$207.11
-0.60%
|
|
ALNY
Alnylam Pharmaceuticals, Inc.
ALNY employs drug delivery platforms (e.g., GalNAc conjugates) enabling targeted and durable RNAi delivery.
|
$47.09B |
$358.97
-0.08%
|
|
INSM
Insmed Incorporated
ARIKAYCE uses a liposomal inhalation drug-delivery platform (Pulmovance) and TPIP is an inhaled prodrug, making Drug Delivery Platforms a core Insmed technology.
|
$34.12B |
$161.53
+1.42%
|
|
BNTX
BioNTech SE
Drug Delivery Platforms cover mRNA delivery and related platforms used to deploy therapies.
|
$26.20B |
$109.00
+2.76%
|
|
PODD
Insulet Corporation
The insulin delivery platform functions as a drug delivery platform enabled by a medical device.
|
$20.25B |
$287.64
+0.40%
|
|
ASND
Ascendis Pharma A/S
TransCon is a proprietary drug-delivery platform enabling long-acting formulations, aligning with Drug Delivery Platforms.
|
$12.46B |
$205.70
-4.34%
|
|
JAZZ
Jazz Pharmaceuticals plc
Jazz's low-sodium formulation (Xywav) reflects a Drug Delivery Platform approach.
|
$10.28B |
$169.37
-1.05%
|
|
RNA
Avidity Biosciences, Inc.
Drug Delivery Platforms: AOC platform is a delivery technology for targeting oligonucleotides to specific tissues.
|
$9.33B |
$72.50
-0.13%
|
|
AXSM
Axsome Therapeutics, Inc.
MoSEIC drug-delivery platform powering Symbravo indicates reliance on Drug Delivery Platforms.
|
$8.85B |
$177.27
+1.80%
|
|
ARWR
Arrowhead Pharmaceuticals, Inc.
TRiM is a drug delivery platform enabling targeted siRNA delivery beyond the liver.
|
$8.83B |
$63.85
-3.62%
|
|
HALO
Halozyme Therapeutics, Inc.
Halozyme's ENHANZE is a proprietary drug-delivery platform enabling rapid, subcutaneous administration of large-volume biologics.
|
$8.33B |
$71.21
-0.85%
|
|
KRYS
Krystal Biotech, Inc.
Krystal's HSV-1 platform functions as a drug-delivery platform enabling redosable gene therapies across organs.
|
$8.25B |
$284.89
+1.02%
|
|
ATR
AptarGroup, Inc.
Aptar markets proprietary drug-delivery platforms (e.g., nasal/inhalation delivery) which are core to its pharma offering.
|
$8.22B |
$124.71
-0.32%
|
|
MTSR
Metsera, Inc.
HALO and MOMENTUM are proprietary drug-delivery platforms enabling extended half-life and oral peptide delivery, i.e., Drug Delivery Platforms.
|
$7.41B |
$70.53
+0.04%
|
|
GKOS
Glaukos Corporation
iDose TR represents a drug delivery platform delivering a sustained intraocular Travoprost formulation.
|
$6.90B |
$120.30
+5.08%
|
|
STVN
Stevanato Group S.p.A.
Provides Drug Delivery Platforms as integrated containment and delivery solutions for biologics.
|
$5.98B |
$19.79
-5.76%
|
|
CDTX
Cidara Therapeutics, Inc.
Cloudbreak is a drug delivery platform (Drug-Fc Conjugate) enabling extended half-life and targeted activity.
|
$5.61B |
$221.39
+0.00%
|
|
CRNX
Crinetics Pharmaceuticals, Inc.
Crinetics' NDC platform and drug-conjugate strategy reflect a drug-delivery platform providing targeted payload delivery.
|
$5.27B |
$55.97
-0.82%
|
|
ALKS
Alkermes plc
Proprietary drug delivery platforms (e.g., LinkeRx, NanoCrystal) used to create extended-release and rapid-dissolution formulations.
|
$5.22B |
$31.62
+1.30%
|
|
PTGX
Protagonist Therapeutics, Inc.
Platform-based drug delivery approach enabling peptide therapeutics.
|
$5.10B |
$81.96
-3.29%
|
|
AKRO
Akero Therapeutics, Inc.
EFX is a biologic drug with a specialized delivery formulation (pre-filled syringe/lyophilized product), placing it squarely in the Drug Delivery Platforms category.
|
$4.37B |
$54.67
+0.04%
|
|
SRRK
Scholar Rock Holding Corporation
Drug Delivery Platforms: platform-based approach enabling targeted modulation of growth factor signaling via antibodies.
|
$4.32B |
$44.98
-3.33%
|
|
AMRX
Amneal Pharmaceuticals, Inc.
Amneal's focus on drug delivery platforms spans multiple complex dosage forms and delivery technologies.
|
$4.21B |
$13.40
+1.63%
|
|
INDV
Indivior PLC
SUBLOCADE's extended-release delivery represents a drug delivery platform (monthly dosing), a core investable theme.
|
$4.06B |
$32.53
-1.06%
|
|
LGND
Ligand Pharmaceuticals Incorporated
Captisol and NITRICIL are platform technologies Ligand licenses/sells to enable drug solubility and tunable dosing, constituting drug delivery platforms.
|
$3.78B |
$193.12
-1.51%
|
|
LQDA
Liquidia Corporation
Liquidia's YUTREPIA is a PRINT-enabled inhaled treprostinil, a drug-delivery platform that enables high-dose, deep-lung delivery and differentiated pharmacokinetics.
|
$3.27B |
$37.90
-2.29%
|
|
BEAM
Beam Therapeutics Inc.
Beam uses lipid nanoparticle (LNP) delivery for in vivo base editing (BEAM-302, BEAM-301), i.e., a Drug Delivery Platform.
|
$3.16B |
$31.23
-2.56%
|
|
SUPN
Supernus Pharmaceuticals, Inc.
Supernus leverages proprietary drug-delivery platforms, notably extended-release formulations, as a core differentiator for its CNS therapies.
|
$2.80B |
$50.04
-0.44%
|
|
DNLI
Denali Therapeutics Inc.
The TransportVehicle platform is a drug delivery platform designed to cross the blood-brain barrier to deliver biologics to the CNS.
|
$2.63B |
$17.98
-4.26%
|
|
DYN
Dyne Therapeutics, Inc.
Dyne's FORCE platform is a drug delivery platform enabling targeted payload delivery to muscle and CNS, making it a core product category.
|
$2.38B |
$16.70
+1.74%
|
|
SLNO
Soleno Therapeutics, Inc.
Drug Delivery Platforms reflects VYKAT XR's extended-release formulation and dosing advantage.
|
$2.26B |
$42.52
+1.35%
|
|
WVE
Wave Life Sciences Ltd.
PRISM delivers oligonucleotides via conjugates (e.g., GalNAc) and non-viral delivery, constituting a drug delivery platform.
|
$2.17B |
$13.65
-2.95%
|
|
ETNB
89bio, Inc.
The company relies on a glycoPEGylation-based drug delivery platform to extend half-life and dosing convenience, representing a Drug Delivery Platforms investable theme.
|
$2.17B |
$14.85
+0.07%
|
|
AVDL
Avadel Pharmaceuticals plc
Avadel uses a proprietary polymer-based extended-release drug-delivery platform to create once-nightly LUMRYZ.
|
$2.09B |
$21.50
+0.07%
|
|
SRPT
Sarepta Therapeutics, Inc.
Drug Delivery Platforms underpin Sarepta's delivery of gene therapies and RNAi assets.
|
$2.06B |
$21.13
-0.84%
|
|
NUVB
Nuvation Bio Inc.
NUV-1511 is based on a Drug-Delivery Platform (DDC), directly describing a drug delivery platform product.
|
$2.00B |
$5.84
-4.80%
|
|
OCUL
Ocular Therapeutix, Inc.
ELUTYX is a proprietary drug-delivery platform central to Ocular Therapeutix's retina-focused pipeline.
|
$1.96B |
$11.27
-0.13%
|
|
IMNM
Immunome, Inc.
HC74 payload and linker optimization reflect a drug delivery platform approach.
|
$1.95B |
$22.43
-1.86%
|
|
ANIP
ANI Pharmaceuticals, Inc.
Development of drug delivery platforms (e.g., Cortrophin Gel pre-filled syringe) demonstrates ANI's drug delivery technology differentiators.
|
$1.84B |
$84.85
-0.52%
|
|
ZYME
Zymeworks Inc.
Drug Delivery Platforms underpin ADC and multispecific payload engineering and delivery.
|
$1.76B |
$23.47
-0.68%
|
|
CLDX
Celldex Therapeutics, Inc.
Drug delivery platforms and subcutaneous formulations are part of Celldex's formulation strategy.
|
$1.70B |
$25.66
-0.12%
|
|
KOD
Kodiak Sciences Inc.
ABC/ABCD platforms are drug delivery technologies enabling sustained ocular release and extended durability.
|
$1.43B |
$27.15
+1.69%
|
|
OCS
Oculis Holding AG
OPTIREACH is a drug delivery platform enabling topical therapies to reach the posterior segment.
|
$1.41B |
$25.23
+5.83%
|
|
BHVN
Biohaven Ltd.
MoDE/TRAP and related platforms constitute drug-delivery platforms enabling targeted degradation of extracellular proteins.
|
$1.39B |
$13.13
+10.15%
|
|
PHVS
Pharvaris N.V.
Pharvaris emphasizes oral delivery with injectable-like efficacy, indicating a Drug Delivery Platforms orientation.
|
$1.37B |
$25.10
-2.14%
|
|
MBX
MBX Biosciences, Inc. Common Stock
MBX is using a drug delivery platform (PEP) to extend action of peptides, enabling less frequent dosing, fitting Drug Delivery Platforms.
|
$1.36B |
$40.56
-0.86%
|
|
NTLA
Intellia Therapeutics, Inc.
Proprietary drug-delivery platform (LNP) enabling in vivo gene editing across programs.
|
$1.34B |
$12.48
+5.18%
|
|
PGEN
Precigen, Inc.
Drug Delivery Platforms tag applies to platform-based delivery mechanisms like AdenoVerse and UltraCAR-T.
|
$1.31B |
$4.39
+6.16%
|
|
NVAX
Novavax, Inc.
Matrix-M is a proprietary vaccine adjuvant/drug-delivery platform used across Novavax's vaccine programs, constituting a major platform technology.
|
$1.30B |
$8.00
+2.76%
|
|
XERS
Xeris Biopharma Holdings, Inc.
Xeris's XeriSol and XeriJect drug-delivery platforms enable stable, ready-to-use injectable formulations, a core differentiator.
|
$1.21B |
$7.53
+1.62%
|
|
AMPH
Amphastar Pharmaceuticals, Inc.
Drug Delivery Platforms captures Amphastar's proprietary delivery systems for injectables, inhalation, and intranasal therapies.
|
$1.21B |
$26.08
+0.31%
|
|
MNMD
Mind Medicine (MindMed) Inc.
MindMed's use of a proprietary oral-dispensing drug-delivery technology constitutes a Drug Delivery Platform.
|
$1.15B |
$15.02
+2072.72%
|
|
CAPR
Capricor Therapeutics, Inc.
StealthX is described as an exosome-based drug delivery platform for targeted cargo delivery.
|
$1.11B |
$24.39
+1.46%
|
|
PVLA
Palvella Therapeutics, Inc.
QTORIN represents a drug delivery platform for localized, topical therapy, a major category in pharmaceutical technology and patient-specific treatments.
|
$1.10B |
$99.88
-3.94%
|
|
SPRY
ARS Pharmaceuticals, Inc.
Neffy uses a proprietary Drug Delivery Platform enabling intranasal delivery of epinephrine.
|
$1.10B |
$11.36
+1.88%
|
|
GHRS
GH Research PLC
GH Research employs an inhalable drug delivery approach for GH001, representing a Drug Delivery Platforms capability.
|
$1.05B |
$17.00
+0.24%
|
|
CVAC
CureVac N.V.
Drug Delivery Platforms captures CureVac's proprietary LNP delivery systems and thermostable formulations integral to its mRNA programs.
|
$1.05B |
$4.66
|
|
INBX
Inhibrx Biosciences, Inc.
Drug delivery platform technology underpinning biologic therapies.
|
$1.05B |
$72.30
+0.70%
|
|
EYPT
EyePoint Pharmaceuticals, Inc.
Core platform technology (Durasert E) used for sustained ocular drug delivery.
|
$1.04B |
$15.08
-4.80%
|
|
OPK
OPKO Health, Inc.
Entera Bio collaboration for oral formulation indicates an emphasis on drug delivery platforms.
|
$1.02B |
$1.29
+0.78%
|
|
TBPH
Theravance Biopharma, Inc.
YUPELRI's nebulized delivery represents a drug delivery platform differentiator for a respiratory therapy.
|
$1.01B |
$20.02
-0.47%
|
|
SVRA
Savara Inc.
Delivery via inhalation (Drug Delivery Platform) is a core aspect of MOLBREEVI's administration method.
|
$1.00B |
$5.58
-3.79%
|
|
PHAT
Phathom Pharmaceuticals, Inc.
Phathom is pursuing an orally disintegrating tablet (ODT) formulation and other delivery innovations for VOQUEZNA, aligning with the drug delivery platforms investable theme.
|
$997.47M |
$14.05
-6.17%
|
|
NBTX
Nanobiotix S.A.
Curadigm and Oocuity are nanoparticle-based platforms aimed at drug delivery and neurally targeted effects, aligning with Drug Delivery Platforms.
|
$995.49M |
$21.00
-0.83%
|
|
VERV
Verve Therapeutics, Inc.
Verve's platform GalNAc-LNP is a proprietary drug delivery system used to target liver cells for gene-editing therapies.
|
$988.30M |
$11.13
|
|
ABUS
Arbutus Biopharma Corporation
Their LNP delivery technology is a drug delivery platform underpinning their RNAi assets.
|
$948.91M |
$4.58
-7.58%
|
|
ATAI
Atai Beckley N.V
Acquisition of IntelGenx adds drug delivery platforms (oral thin-film) powering VLS-01 and related assets.
|
$919.51M |
$4.16
-3.03%
|
|
CTMX
CytomX Therapeutics, Inc.
PROBODY is a drug delivery platform designed to localize activity to tumors, fitting Drug Delivery Platforms.
|
$888.88M |
$5.39
+26.94%
|
|
URGN
UroGen Pharma Ltd.
RTGel is a drug-delivery platform used by UroGen for localized, extended-release therapy.
|
$869.77M |
$18.85
-3.53%
|
|
PCRX
Pacira BioSciences, Inc.
Pacira's pMVL-based Drug Delivery Platforms enable extended-release formulations used in EXPAREL and ZILRETTA.
|
$860.91M |
$19.14
-7.31%
|
|
FLGT
Fulgent Genetics, Inc.
Drug delivery platforms including nanoencapsulation.
|
$859.50M |
$28.10
-1.92%
|
|
VIR
Vir Biotechnology, Inc.
PRO-XTEN masking platform represents a drug delivery platform intended to improve safety and therapeutic index.
|
$841.83M |
$6.07
-2.10%
|
|
KE
Kimball Electronics, Inc.
Drug delivery platforms are a targeted medical technology offering within KE's Medical CMO scope.
|
$746.66M |
$30.75
-2.01%
|
|
NKTR
Nektar Therapeutics
PEGylation is a drug-delivery platform approach used to optimize pharmacokinetics and dosing.
|
$716.62M |
$37.65
+6.48%
|
|
RGNX
REGENXBIO Inc.
NAV platform involves drug delivery platform technology.
|
$688.00M |
$13.64
-0.84%
|
|
SRDX
Surmodics, Inc.
The company provides proprietary drug-delivery platform technologies used on medical devices (SurVeil DCB) and related platforms.
|
$614.58M |
$42.98
|
|
MGTX
MeiraGTx Holdings plc
Riboswitch platform represents a drug delivery platform enabling regulated transgene expression, a core technology.
|
$607.38M |
$7.40
-1.99%
|
|
HYEX
Healthy Extracts Inc.
Exclusive rights to an oral delivery technology for nutritional supplements, a distinctive platform that differentiates the company’s product delivery.
|
$593.59M |
$1.94
|
|
GOSS
Gossamer Bio, Inc.
Inhaled seralutinib represents a drug-delivery platform that concentrates therapy in the lungs to treat pulmonary hypertension, a major differentiator.
|
$573.00M |
$2.52
+3.06%
|
|
DBVT
DBV Technologies S.A.
Viaskin Peanut EPIT patch is a drug-delivery platform; DBV Technologies directly develops and commercializes this patch-based immunotherapy.
|
$569.26M |
$20.74
+10.32%
|
|
REPL
Replimune Group, Inc.
RPx platform functions as a drug delivery platform enabling multi-gene payload immunotherapies.
|
$549.51M |
$7.03
-3.77%
|
|
PRME
Prime Medicine, Inc.
Leverages a drug delivery platform (universal liver LNP with GalNAc targeting) to enable in vivo gene editing.
|
$535.60M |
$3.98
-0.25%
|
|
DSGN
Design Therapeutics, Inc.
GeneTAC platform implies a drug delivery/modulation approach, aligning with a Drug Delivery Platforms category.
|
$528.48M |
$9.27
-0.96%
|
|
ENGN
enGene Holdings Inc.
DDX platform is a drug delivery technology enabling localized genetic medicines, a distinct product category.
|
$476.60M |
$9.34
+1.30%
|
|
ZVRA
Zevra Therapeutics, Inc.
LAT platform enables prodrug drug delivery platforms, representing a proprietary drug-delivery platform technology.
|
$466.48M |
$8.48
+2.05%
|
|
ANRO
Alto Neuroscience, Inc.
Drug delivery platform to enable targeted or improved administration of Alto's CNS therapeutics (e.g., transdermal PDE4 inhibitor).
|
$464.91M |
$17.21
+1.12%
|
|
PRTC
PureTech Health plc
Glyph platform is a drug-delivery technology enabling oral administration of therapies.
|
$459.99M |
$19.23
+0.29%
|
|
BCYC
Bicycle Therapeutics plc
Platform enables targeted delivery and payload conjugation for therapeutics (drug delivery platform).
|
$451.19M |
$6.53
+0.93%
|
|
TRDA
Entrada Therapeutics, Inc.
Entrata's primary value proposition is its Drug Delivery Platform (EEV) enabling intracellular delivery of therapeutics.
|
$418.41M |
$11.00
+1.66%
|
|
CLPT
ClearPoint Neuro, Inc.
SmartFlow cannula represents a drug-delivery platform for targeted brain infusion, tied to cell/gene therapy delivery approaches.
|
$416.46M |
$14.65
+0.03%
|
|
CYBN
Cybin Inc.
CYB004 utilizes a deuterated drug delivery approach including an inhalation platform, indicating a Drug Delivery Platforms capability.
|
$413.12M |
$8.30
+1.53%
|
|
ADCT
ADC Therapeutics S.A.
ADCT emphasizes a proprietary Drug Delivery Platform powering its ADC payloads and conjugation chemistries.
|
$407.25M |
$3.62
+1.97%
|
|
LXEO
Lexeo Therapeutics, Inc. Common Stock
Uses a drug delivery platform (AAV vectors) to deliver genes, constituting a drug delivery platform business line.
|
$399.07M |
$7.41
-1.27%
|
|
AURA
Aura Biosciences, Inc.
Aura's VDC platform is a drug delivery platform enabling targeted, light-activated therapy.
|
$393.22M |
$6.16
-2.69%
|
|
DMAC
DiaMedica Therapeutics Inc.
DM199 represents a drug-delivery/therapeutic platform with IV administration and ongoing manufacturing development.
|
$391.54M |
$7.61
-10.95%
|
|
LCTX
Lineage Cell Therapeutics, Inc.
Lineage emphasizes a drug delivery platform and formulation (cryopreserved thaw-and-inject formulations) enabling scalable, ready-to-administer cell therapies.
|
$388.21M |
$1.70
+3.03%
|
|
MNPR
Monopar Therapeutics Inc.
MNPR-101 platform represents a drug delivery platform for radiopharmaceuticals, enabling targeted delivery and radionuclide conjugation.
|
$380.87M |
$56.59
-8.33%
|
|
TLSI
TriSalus Life Sciences, Inc.
Core PEDD drug-delivery platform technology powering TriNav systems.
|
$370.02M |
$7.32
+0.48%
|
Showing page 1 of 3 (230 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
